目的以24 h尿钠排泄水平(24 h UNa)作为钠摄入量评估指标,评估不同钠盐的摄入水平与血清炎症因子对2型糖尿病(T2DM)患者尿白蛋白(UA)发生风险的影响。方法纳入T2DM患者130例,依据尿白蛋白/肌酐比值(UACR)水平分为UA阳性组60例和UA阴性...目的以24 h尿钠排泄水平(24 h UNa)作为钠摄入量评估指标,评估不同钠盐的摄入水平与血清炎症因子对2型糖尿病(T2DM)患者尿白蛋白(UA)发生风险的影响。方法纳入T2DM患者130例,依据尿白蛋白/肌酐比值(UACR)水平分为UA阳性组60例和UA阴性组70例。收集患者的临床资料,检测炎性因子及24 h尿液相关指标。采用Spearman相关分析T2DM患者临床指标与UACR的相关性;二元Logistic回归分析T2DM患者临床指标对UA的影响;二分类回归法分析24 h UNa和IL-18关联对UA的影响。结果24 h UNa水平(OR=1.019,95%CI 1.003~1.035,P=0.017)与IL-18(OR=1.204,95%CI 1.060~1.368,P=0.004)是T2DM患者UA阳性的独立危险因素。联合分析提示,与低钠低IL-18组比较,高钠高IL-18组UA阳性风险显著增加(OR=10.774,95%CI 2.105~55.155,P=0.004)。结论24 h UNa、IL-18水平升高是T2DM患者UA发生的危险因素。展开更多
目的:探究重症肺炎患者血清APC,IL-18的表达及其与临床预后的相关性。方法:选取2022年1月~2024年1月我院收治的76例重症肺炎患者作为研究组,选择同期的76名到我院进行体检的健康人员作为对照组,全部研究对象均接受血清APC,IL-18指标的...目的:探究重症肺炎患者血清APC,IL-18的表达及其与临床预后的相关性。方法:选取2022年1月~2024年1月我院收治的76例重症肺炎患者作为研究组,选择同期的76名到我院进行体检的健康人员作为对照组,全部研究对象均接受血清APC,IL-18指标的检测。结果:研究组的血清APC水平更低(P Objective: To investigate the expression of serum APC and IL-18 in patients with severe pneumonia and their correlation with clinical prognosis. Method: 76 severe pneumonia patients admitted to our hospital from January 2022 to January 2024 were selected as the study group, and 76 healthy individuals who came to our hospital for physical examination during the same period were selected as the control group. All study subjects underwent serum APC and IL-18 index detection. Result: The serum APC level in the study group was lower (P < 0.05), and the IL-18 level in the study group was higher (P < 0.05);The regression analysis results showed that the levels of serum IL-18 and APC were related to the clinical prognosis of patients with severe pneumonia (P < 0.05);There is a significant positive correlation (P < 0.05) between different prognostic outcomes and serum IL-18 levels, and a significant negative correlation (P < 0.05) between different prognostic outcomes and serum APC levels. Conclusion: Compared with healthy individuals, patients with severe pneumonia show significant changes in serum APC and IL-18 indicators, which also have a significant impact on the prognosis of severe pneumonia patients, providing important reference for subsequent clinical diagnosis and treatment.展开更多
目的:观察四妙丸对高尿酸性肾病患者血尿酸水平、肾功能及血清IL-1β、IL-18炎症因子分泌的影响。方法:选择90例高尿酸性肾病患者,随机分为非布司他组、四妙丸组和综合治疗组(非布司他+四妙丸),监测每组患者血尿酸、血肌酐水平,同时利用...目的:观察四妙丸对高尿酸性肾病患者血尿酸水平、肾功能及血清IL-1β、IL-18炎症因子分泌的影响。方法:选择90例高尿酸性肾病患者,随机分为非布司他组、四妙丸组和综合治疗组(非布司他+四妙丸),监测每组患者血尿酸、血肌酐水平,同时利用Elisa试剂盒测定血清IL-1β、IL-18炎症因子的分泌水平。结果:(1)血尿酸水平方面,非布司他组、综合治疗组2月时与0月相比即差异有统计学意义(414.03±41.21 vs 457.70±55.67,416.26±41.57 vs 486.56±63.32,P<0.05);四妙丸组3月时与0月比较差异有统计学意义(389.26±62.59 vs 456.23±66.77,P<0.05);3月时,综合治疗组与四妙丸组比较下降明显(353.0±70.12 vs 389.26.65±62.59,P<0.05)。(2)血肌酐水平方面,综合治疗组2月时与0月比较即明显降低(245.83±73.0 vs 311.76±88.48,P<0.05);四妙丸组3月时与0月比较显著下降(239.30±76.11 vs 291.50±94.72,P<0.05);3月时,与非布司他组相比,综合治疗组肌酐水平下降明显(209.9±56.62 vs 252.70±73.37,P<0.05);(3)血清炎症因子方面,非布司他组、四妙丸组、综合治疗组与0月时比较血清IL-1β水平(36.20±3.97 vs 40.0±5.89,29.66±7.62 vs 40.16±6.59,23.46±3.71 vs 41.63±4.88,P<0.05)、IL-18水平(67.13±3.27 vs 81.10±5.29,58.73±6.08 vs 78.76±4.90,49.93±5.13 vs 80.30±5.34,P<0.05)均显著下降;3月时,与非布司他组相比,四妙丸组、综合治疗组血清IL-1β水平(29.66±7.62 vs 36.20±3.97,23.46±3.71 vs 36.20±3.97,P<0.05)、IL-18水平(58.73±6.08 vs 67.13±3.27,49.93±5.13 vs 67.13±3.27,P<0.05)下降更为明显。结论:四妙丸能够通过降低血尿酸水平及抑制血清IL-1β、IL-18炎症因子的分泌对高尿酸性肾病患者产生肾脏保护作用。展开更多
文摘目的以24 h尿钠排泄水平(24 h UNa)作为钠摄入量评估指标,评估不同钠盐的摄入水平与血清炎症因子对2型糖尿病(T2DM)患者尿白蛋白(UA)发生风险的影响。方法纳入T2DM患者130例,依据尿白蛋白/肌酐比值(UACR)水平分为UA阳性组60例和UA阴性组70例。收集患者的临床资料,检测炎性因子及24 h尿液相关指标。采用Spearman相关分析T2DM患者临床指标与UACR的相关性;二元Logistic回归分析T2DM患者临床指标对UA的影响;二分类回归法分析24 h UNa和IL-18关联对UA的影响。结果24 h UNa水平(OR=1.019,95%CI 1.003~1.035,P=0.017)与IL-18(OR=1.204,95%CI 1.060~1.368,P=0.004)是T2DM患者UA阳性的独立危险因素。联合分析提示,与低钠低IL-18组比较,高钠高IL-18组UA阳性风险显著增加(OR=10.774,95%CI 2.105~55.155,P=0.004)。结论24 h UNa、IL-18水平升高是T2DM患者UA发生的危险因素。
文摘目的:探究重症肺炎患者血清APC,IL-18的表达及其与临床预后的相关性。方法:选取2022年1月~2024年1月我院收治的76例重症肺炎患者作为研究组,选择同期的76名到我院进行体检的健康人员作为对照组,全部研究对象均接受血清APC,IL-18指标的检测。结果:研究组的血清APC水平更低(P Objective: To investigate the expression of serum APC and IL-18 in patients with severe pneumonia and their correlation with clinical prognosis. Method: 76 severe pneumonia patients admitted to our hospital from January 2022 to January 2024 were selected as the study group, and 76 healthy individuals who came to our hospital for physical examination during the same period were selected as the control group. All study subjects underwent serum APC and IL-18 index detection. Result: The serum APC level in the study group was lower (P < 0.05), and the IL-18 level in the study group was higher (P < 0.05);The regression analysis results showed that the levels of serum IL-18 and APC were related to the clinical prognosis of patients with severe pneumonia (P < 0.05);There is a significant positive correlation (P < 0.05) between different prognostic outcomes and serum IL-18 levels, and a significant negative correlation (P < 0.05) between different prognostic outcomes and serum APC levels. Conclusion: Compared with healthy individuals, patients with severe pneumonia show significant changes in serum APC and IL-18 indicators, which also have a significant impact on the prognosis of severe pneumonia patients, providing important reference for subsequent clinical diagnosis and treatment.
文摘目的:观察四妙丸对高尿酸性肾病患者血尿酸水平、肾功能及血清IL-1β、IL-18炎症因子分泌的影响。方法:选择90例高尿酸性肾病患者,随机分为非布司他组、四妙丸组和综合治疗组(非布司他+四妙丸),监测每组患者血尿酸、血肌酐水平,同时利用Elisa试剂盒测定血清IL-1β、IL-18炎症因子的分泌水平。结果:(1)血尿酸水平方面,非布司他组、综合治疗组2月时与0月相比即差异有统计学意义(414.03±41.21 vs 457.70±55.67,416.26±41.57 vs 486.56±63.32,P<0.05);四妙丸组3月时与0月比较差异有统计学意义(389.26±62.59 vs 456.23±66.77,P<0.05);3月时,综合治疗组与四妙丸组比较下降明显(353.0±70.12 vs 389.26.65±62.59,P<0.05)。(2)血肌酐水平方面,综合治疗组2月时与0月比较即明显降低(245.83±73.0 vs 311.76±88.48,P<0.05);四妙丸组3月时与0月比较显著下降(239.30±76.11 vs 291.50±94.72,P<0.05);3月时,与非布司他组相比,综合治疗组肌酐水平下降明显(209.9±56.62 vs 252.70±73.37,P<0.05);(3)血清炎症因子方面,非布司他组、四妙丸组、综合治疗组与0月时比较血清IL-1β水平(36.20±3.97 vs 40.0±5.89,29.66±7.62 vs 40.16±6.59,23.46±3.71 vs 41.63±4.88,P<0.05)、IL-18水平(67.13±3.27 vs 81.10±5.29,58.73±6.08 vs 78.76±4.90,49.93±5.13 vs 80.30±5.34,P<0.05)均显著下降;3月时,与非布司他组相比,四妙丸组、综合治疗组血清IL-1β水平(29.66±7.62 vs 36.20±3.97,23.46±3.71 vs 36.20±3.97,P<0.05)、IL-18水平(58.73±6.08 vs 67.13±3.27,49.93±5.13 vs 67.13±3.27,P<0.05)下降更为明显。结论:四妙丸能够通过降低血尿酸水平及抑制血清IL-1β、IL-18炎症因子的分泌对高尿酸性肾病患者产生肾脏保护作用。
